EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Trials for Slowly Progressive Neurogenetic Diseases Need Surrogate Endpoints

Mary M Reilly, David N Herrmann, Davide Pareyson iD, Steven S Scherer, Richard S Finkel, Stephan Züchner, Joshua Burns, Michael E Shy iD

Annals of Neurology · 2023-05 · 93 (5) · 906-910

DOI: 10.1002/ana.26633 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Annals of Neurology, online erschienen am 21.03.2023. Verfasst von Mary M Reilly und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neuromuscular Diseases, UCL Queen Square Institute of Neurology, London, UK. Hauptthemen laut MEDLINE: Peripheral Nervous System Diseases, Nervous System Diseases. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NINDS NIH HHS, Muscular Dystrophy Association, National Institute of Neurological Disorders and Stroke.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Heritable neurological disorders provide insights into disease mechanisms that permit development of novel therapeutic approaches including antisense oligonucleotides, RNA interference, and gene replacement. Many neurogenetic diseases are rare and slowly progressive making it challenging to measure disease progression within short time frames. We share our experience developing clinical outcome assessments and disease biomarkers in the inherited peripheral neuropathies. We posit that carefully developed biomarkers from imaging, plasma, or skin can predict meaningful progression in functional and patient reported outcome assessments such that clinical trials of less than 2 years will be feasible for these rare and ultra‐rare disorders. ANN NEUROL 2023;93:906–910

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Peripheral Nervous System DiseasesNervous System DiseasesHumansBiomarkers

Substanzen

Biomarkers

Autor:innen und Institutionen

  • Department of Neuromuscular Diseases, UCL Queen Square Institute of Neurology, London, UK.
  • Department of Neurology, University of Rochester, Rochester, NY.
  • Unit of Rare Neurodegenerative and Neurometabolic Diseases, Department of Clinical Neurosciences, Fondazione IRRCCS Istituto Neurologico Carlo Besta, Milan, Italy.
  • Department of Neurology, The Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA.
  • Center for Experimental Neurotherapeutics, St. Jude Children's Research Hospital, Memphis, TN.
  • Dr. John T. Macdonald Foundation Department of Human Genetics and John P. Hussman Institute for Human Genomics, University of Miami Miller School of Medicine, Miami, FL.

ORCID-Profile: Davide Pareyson, Michael E Shy

Förderung

  • NINDS NIH HHS
  • Muscular Dystrophy Association
  • National Institute of Neurological Disorders and Stroke

Zitieren

APA

Reilly, M. M., Herrmann, D. N., Pareyson, D., Scherer, S. S., Finkel, R. S., Züchner, S., Burns, J., & Shy, M. E. (2023). Trials for Slowly Progressive Neurogenetic Diseases Need Surrogate Endpoints. Annals of Neurology, 93(5), 906-910. https://doi.org/10.1002/ana.26633

Vancouver

Reilly MM, Herrmann DN, Pareyson D, Scherer SS, Finkel RS, Züchner S, et al. Trials for Slowly Progressive Neurogenetic Diseases Need Surrogate Endpoints. Annals of Neurology. 2023;93(5):906-910. doi:10.1002/ana.26633

BibTeX
@article{Reilly2023,
  author = {Reilly, Mary M and Herrmann, David N and Pareyson, Davide and Scherer, Steven S and Finkel, Richard S and Züchner, Stephan and Burns, Joshua and Shy, Michael E},
  title = {Trials for Slowly Progressive Neurogenetic Diseases Need Surrogate Endpoints},
  journal = {Annals of Neurology},
  year = {2023},
  volume = {93},
  number = {5},
  pages = {906--910},
  doi = {10.1002/ana.26633}
}
Kostenlos starten →